Fig. 3.

Challenge of “vaccinated” mice. For both groups (B16F10 and LLC), mice received a cell-based Reovirus vaccine 8–12 weeks prior to day 0. Survival of (a) B16F10 and (b) LLC vaccinated mice compared to naïve controls. In both incidences vaccinated mice survived beyond 100 days which was deemed to be curative. Unvaccinated mice developed tumours within 10 days for B16F10 inoculated mice (c) and 7 days for LLC inoculated (d)